Regeneron Pharmaceuticals on Friday announced that the Food and Drug Administration has approved Eylea HD Injection 8 mg for the treatment of patients with wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy. The recommended dose for Eylea HD is 8 mg every four weeks for the first three months across all indications.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on REGN:
- Regeneron Stock (NASDAQ:REGN): Analysts are Bullish Post FDA Approval
- EYLEA HD (aflibercept) Injection 8 mg Approved by FDA for Treatment of Wet Age-related Macular Degeneration (wAMD), Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR)
- RBC says Regeneron news intimates high-dose Eylea approval likely
- Regeneron announces FDA approval of Veopoz for Chaple disease
- Veopoz™ (pozelimab-bbfg) Receives FDA Approval as the First Treatment for Children and Adults with CHAPLE Disease